Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults
- PMID: 25916341
- DOI: 10.1056/NEJMoa1501184
Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults
Abstract
Background: In previous phase 1-2 clinical trials involving older adults, a subunit vaccine containing varicella-zoster virus glycoprotein E and the AS01B adjuvant system (called HZ/su) had a clinically acceptable safety profile and elicited a robust immune response.
Methods: We conducted a randomized, placebo-controlled, phase 3 study in 18 countries to evaluate the efficacy and safety of HZ/su in older adults (≥50 years of age), stratified according to age group (50 to 59, 60 to 69, and ≥70 years). Participants received two intramuscular doses of the vaccine or placebo 2 months apart. The primary objective was to assess the efficacy of the vaccine, as compared with placebo, in reducing the risk of herpes zoster in older adults.
Results: A total of 15,411 participants who could be evaluated received either the vaccine (7698 participants) or placebo (7713 participants). During a mean follow-up of 3.2 years, herpes zoster was confirmed in 6 participants in the vaccine group and in 210 participants in the placebo group (incidence rate, 0.3 vs. 9.1 per 1000 person-years) in the modified vaccinated cohort. Overall vaccine efficacy against herpes zoster was 97.2% (95% confidence interval [CI], 93.7 to 99.0; P<0.001). Vaccine efficacy was between 96.6% and 97.9% for all age groups. Solicited reports of injection-site and systemic reactions within 7 days after vaccination were more frequent in the vaccine group. There were solicited or unsolicited reports of grade 3 symptoms in 17.0% of vaccine recipients and 3.2% of placebo recipients. The proportions of participants who had serious adverse events or potential immune-mediated diseases or who died were similar in the two groups.
Conclusions: The HZ/su vaccine significantly reduced the risk of herpes zoster in adults who were 50 years of age or older. Vaccine efficacy in adults who were 70 years of age or older was similar to that in the other two age groups. (Funded by GlaxoSmithKline Biologicals; ZOE-50 ClinicalTrials.gov number, NCT01165177.).
Comment in
-
A new vaccine to prevent herpes zoster.N Engl J Med. 2015 May 28;372(22):2149-50. doi: 10.1056/NEJMe1505050. Epub 2015 Apr 28. N Engl J Med. 2015. PMID: 25916342 Free PMC article. No abstract available.
-
Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.N Engl J Med. 2015 Oct 15;373(16):1576-7. doi: 10.1056/NEJMc1508392. N Engl J Med. 2015. PMID: 26465999 No abstract available.
-
Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.N Engl J Med. 2015 Oct 15;373(16):1575-6. doi: 10.1056/NEJMc1508392. N Engl J Med. 2015. PMID: 26466000 No abstract available.
-
Adjuvanted Herpes Zoster Subunit Vaccine in Older Adults.N Engl J Med. 2015 Oct 15;373(16):1576. doi: 10.1056/NEJMc1508392. N Engl J Med. 2015. PMID: 26466001 No abstract available.
Similar articles
-
Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.Vaccine. 2018 Jan 2;36(1):148-154. doi: 10.1016/j.vaccine.2017.11.019. Epub 2017 Nov 22. Vaccine. 2018. PMID: 29174683 Clinical Trial.
-
Vaccine profile of herpes zoster (HZ/su) subunit vaccine.Expert Rev Vaccines. 2017 Jul;16(7):1-10. doi: 10.1080/14760584.2017.1329012. Epub 2017 May 19. Expert Rev Vaccines. 2017. PMID: 28486850 Review.
-
Immunogenicity and safety of an adjuvanted herpes zoster subunit candidate vaccine in adults ≥ 50 years of age with a prior history of herpes zoster: A phase III, non-randomized, open-label clinical trial.Hum Vaccin Immunother. 2017 May 4;13(5):1051-1058. doi: 10.1080/21645515.2016.1265715. Epub 2017 Jan 9. Hum Vaccin Immunother. 2017. PMID: 28068212 Free PMC article. Clinical Trial.
-
Efficacy of the Herpes Zoster Subunit Vaccine in Adults 70 Years of Age or Older.N Engl J Med. 2016 Sep 15;375(11):1019-32. doi: 10.1056/NEJMoa1603800. N Engl J Med. 2016. PMID: 27626517 Clinical Trial.
-
Vaccines for preventing herpes zoster in older adults.Cochrane Database Syst Rev. 2016 Mar 3;3(3):CD008858. doi: 10.1002/14651858.CD008858.pub3. Cochrane Database Syst Rev. 2016. Update in: Cochrane Database Syst Rev. 2019 Nov 7;2019(11). doi: 10.1002/14651858.CD008858.pub4. PMID: 26937872 Free PMC article. Updated. Review.
Cited by
-
Herpes Zoster Ophthalmicus: Presentation, Complications, Treatment, and Prevention.Infect Dis Ther. 2024 Jul;13(7):1439-1459. doi: 10.1007/s40121-024-00990-7. Epub 2024 Jun 4. Infect Dis Ther. 2024. PMID: 38834857 Free PMC article. Review.
-
Public health impact of herpes zoster vaccination on older adults in Singapore: a modeling study.Hum Vaccin Immunother. 2024 Dec 31;20(1):2348839. doi: 10.1080/21645515.2024.2348839. Epub 2024 May 28. Hum Vaccin Immunother. 2024. PMID: 38804600 Free PMC article.
-
Immunogenicity of Recombinant Zoster Vaccine: A Systematic Review, Meta-Analysis, and Meta-Regression.Vaccines (Basel). 2024 May 11;12(5):527. doi: 10.3390/vaccines12050527. Vaccines (Basel). 2024. PMID: 38793778 Free PMC article. Review.
-
Vaccines and the Eye: Current Understanding of the Molecular and Immunological Effects of Vaccination on the Eye.Int J Mol Sci. 2024 Apr 26;25(9):4755. doi: 10.3390/ijms25094755. Int J Mol Sci. 2024. PMID: 38731972 Free PMC article. Review.
-
Cross-protection against influenza viruses by chimeric M2e-H3 stalk protein or multi-subtype neuraminidase plus M2e virus-like particle vaccine in ferrets.Virology. 2024 Jul;595:110097. doi: 10.1016/j.virol.2024.110097. Epub 2024 Apr 25. Virology. 2024. PMID: 38685171
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical